Annual CFO
-$149.55 M
-$27.22 M-22.25%
31 December 2023
Summary:
Verve Therapeutics annual cash flow from operations is currently -$149.55 million, with the most recent change of -$27.22 million (-22.25%) on 31 December 2023. During the last 3 years, it has fallen by -$114.28 million (-324.07%). VERV annual CFO is now -1909.53% below its all-time high of -$7.44 million, reached on 31 December 2019.VERV Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$39.61 M
-$5.45 M-15.95%
30 September 2024
Summary:
Verve Therapeutics quarterly cash flow from operations is currently -$39.61 million, with the most recent change of -$5.45 million (-15.95%) on 30 September 2024. Over the past year, it has dropped by -$27.80 million (-235.34%). VERV quarterly CFO is now -526.30% below its all-time high of -$6.32 million, reached on 30 September 2020.VERV Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$157.53 M
-$27.80 M-21.43%
30 September 2024
Summary:
Verve Therapeutics TTM cash flow from operations is currently -$157.53 million, with the most recent change of -$27.80 million (-21.43%) on 30 September 2024. Over the past year, it has dropped by -$15.77 million (-11.12%). VERV TTM CFO is now -2209.10% below its all-time high of -$6.82 million, reached on 31 March 2020.VERV TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VERV Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.3% | -235.3% | -11.1% |
| 3 y3 years | -324.1% | -85.5% | -143.1% |
| 5 y5 years | - | - | - |
VERV Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -324.1% | at low | -235.3% | +19.3% | -143.1% | +1.0% |
| 5 y | 5 years | -1909.5% | at low | -526.3% | +19.3% | -2209.1% | +1.0% |
| alltime | all time | -1909.5% | at low | -526.3% | +19.3% | -2209.1% | +1.0% |
Verve Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$39.61 M(+16.0%) | -$157.53 M(+21.4%) |
| June 2024 | - | -$34.16 M(-20.7%) | -$129.73 M(-9.6%) |
| Mar 2024 | - | -$43.08 M(+5.9%) | -$143.53 M(-4.0%) |
| Dec 2023 | -$149.55 M(+22.2%) | -$40.68 M(+244.4%) | -$149.55 M(+5.5%) |
| Sept 2023 | - | -$11.81 M(-75.4%) | -$141.76 M(-10.9%) |
| June 2023 | - | -$47.96 M(-2.3%) | -$159.13 M(+15.4%) |
| Mar 2023 | - | -$49.10 M(+49.3%) | -$137.92 M(+12.7%) |
| Dec 2022 | -$122.33 M | -$32.89 M(+12.7%) | -$122.33 M(+4.1%) |
| Sept 2022 | - | -$29.18 M(+9.0%) | -$117.48 M(+7.1%) |
| June 2022 | - | -$26.76 M(-20.1%) | -$109.66 M(+13.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$33.51 M(+19.5%) | -$96.25 M(+23.6%) |
| Dec 2021 | -$77.88 M(+120.8%) | -$28.04 M(+31.3%) | -$77.88 M(+20.2%) |
| Sept 2021 | - | -$21.36 M(+60.1%) | -$64.81 M(+30.2%) |
| June 2021 | - | -$13.34 M(-11.9%) | -$49.78 M(+14.2%) |
| Mar 2021 | - | -$15.14 M(+1.1%) | -$43.58 M(+23.6%) |
| Dec 2020 | -$35.27 M(+373.9%) | - | - |
| Dec 2020 | - | -$14.97 M(+136.8%) | -$35.27 M(+73.8%) |
| Sept 2020 | - | -$6.32 M(-11.5%) | -$20.29 M(+45.3%) |
| June 2020 | - | -$7.14 M(+4.7%) | -$13.97 M(+104.7%) |
| Mar 2020 | - | -$6.82 M | -$6.82 M |
| Dec 2019 | -$7.44 M | - | - |
FAQ
- What is Verve Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Verve Therapeutics?
- What is Verve Therapeutics annual CFO year-on-year change?
- What is Verve Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Verve Therapeutics?
- What is Verve Therapeutics quarterly CFO year-on-year change?
- What is Verve Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Verve Therapeutics?
- What is Verve Therapeutics TTM CFO year-on-year change?
What is Verve Therapeutics annual cash flow from operations?
The current annual CFO of VERV is -$149.55 M
What is the all time high annual CFO for Verve Therapeutics?
Verve Therapeutics all-time high annual cash flow from operations is -$7.44 M
What is Verve Therapeutics annual CFO year-on-year change?
Over the past year, VERV annual cash flow from operations has changed by -$27.22 M (-22.25%)
What is Verve Therapeutics quarterly cash flow from operations?
The current quarterly CFO of VERV is -$39.61 M
What is the all time high quarterly CFO for Verve Therapeutics?
Verve Therapeutics all-time high quarterly cash flow from operations is -$6.32 M
What is Verve Therapeutics quarterly CFO year-on-year change?
Over the past year, VERV quarterly cash flow from operations has changed by -$27.80 M (-235.34%)
What is Verve Therapeutics TTM cash flow from operations?
The current TTM CFO of VERV is -$157.53 M
What is the all time high TTM CFO for Verve Therapeutics?
Verve Therapeutics all-time high TTM cash flow from operations is -$6.82 M
What is Verve Therapeutics TTM CFO year-on-year change?
Over the past year, VERV TTM cash flow from operations has changed by -$15.77 M (-11.12%)